Provided by Tiger Trade Technology Pte. Ltd.

Vertex Pharmaceuticals

461.94
+0.69500.15%
Volume:331.17K
Turnover:153.95M
Market Cap:117.20B
PE:32.48
High:469.00
Open:462.50
Low:460.00
Close:461.24
52wk High:519.68
52wk Low:362.50
Shares:253.72M
Float Shares:253.72M
Volume Ratio:0.55
T/O Rate:0.13%
Dividend:- -
Dividend Rate:- -
EPS(TTM):14.22
EPS(LYR):-2.0768
ROE:22.31%
ROA:12.04%
PB:6.77
PE(LYR):-222.43

Loading ...

Morgan Stanley Cuts Price Target on Vertex to $20 From $33, Keeps Overweight Rating

MT Newswires Live
·
Yesterday

Vertex 9-Mos Net Y9.00B Vs Net Y3.01B

Dow Jones
·
Yesterday

Vertex downgraded to Hold from Buy at Jefferies

TIPRANKS
·
Yesterday

Vertex Is Maintained at Buy by Needham

Dow Jones
·
Yesterday

Vertex price target lowered to $16 from $23 at Stifel

TIPRANKS
·
Yesterday

Vertex: Compressed Valuation, Scaling FCF, and SAP-Driven ARR Catalysts Support Buy Rating

TIPRANKS
·
Yesterday

Vertex Pharmaceuticals’ povetacicept granted FDA orphan designation

TIPRANKS
·
Feb 11

Vertex Pharmaceuticals at Turning Point Ahead of Phase 3 Kidney Drug Data, RBC Says

MT Newswires Live
·
Feb 11

RBC Capital Sticks to Its Buy Rating for Vertex Pharmaceuticals (VRTX)

TIPRANKS
·
Feb 10

Vertex Pharmaceuticals Inc. Stock Underperforms Monday When Compared To Competitors

Dow Jones
·
Feb 10

Vertex Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Feb 07

WuXi Biologics Alliances Deepen Role In Complex Autoimmune And Fusion Drugs

Simply Wall St.
·
Feb 06

Prestige Consumer Healthcare Q3 2026 revenue at USD 283.4 million, down 2.4%

Reuters
·
Feb 05

Does WuXi Trispecific T-cell Engager Deal Reshape the Bull Case for Vertex Pharmaceuticals (VRTX)?

Simply Wall St.
·
Feb 05

Earning Preview: Vertex Pharmaceuticals this quarter’s revenue is expected to increase by 14.16%, and institutional views are bullish

Earnings Agent
·
Feb 05

Vertex Minerals Lifts High-Grade Output as Reward Gold Mine Ramps Up Underground Stoping

TIPRANKS
·
Feb 05

Vertex Pharmaceuticals Inc. Stock Underperforms Tuesday When Compared To Competitors

Dow Jones
·
Feb 04

Vertex Pharmaceuticals Files Initial Statement of Beneficial Ownership for Mark E. Bunnage, EVP and Chief Scientific Officer

Reuters
·
Feb 04

Vertex Report: U.S. Sees Record-Level Growth in Sales Tax Rates and Rules Changes in 2025 Amid Fiscal Uncertainty

GlobeNewswire
·
Feb 03

Piper Sandler Downgrades Vertex to Neutral From Overweight

MT Newswires Live
·
Feb 03